All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
AbbVie to invest $195m in new API production facility in US
The expansion will bolster AbbVie’s domestic API production, supporting advancements in neuroscience, immunology, and oncology medicines.
Insmed secures FDA approval for Brinsupri to treat NCFB
Brinsupri is a DPP1-inhibitor, indicated for the treatment of adults and children with NCFB, aged 12 years and above.
Novartis’ Phase 3 trials of ianalumab meet primary endpoints
The primary endpoints of both trials were measured by improvements in disease activity using the ESSDAI, compared to a placebo.
Fosun Pharma, Expedition enter $645m licensing deal for XH-S004
The agreement provides Expedition with rights outside Chinese Mainland, Hong Kong SAR, and Macau SAR, while Fosun retains rights within these regions.
US FDA approves Boehringer’s Hernexeos for HER2-positive NSCLC
Hernexeos, a tyrosine kinase inhibitor that selectively targets HER2, is the first oral targeted therapy approved for HER2-mutant advanced NSCLC.
CureVac, GSK settle mRNA patent litigation with Pfizer, BioNTech
The settlement involves a combined payment of $740m to CureVac and GSK, alongside single-digit royalties on US sales of Covid-19 vaccines.
XtalPi and DoveTree enter $6bn AI drug discovery partnership
XtalPi will leverage its AI and robotics expertise, while DoveTree will its biological insights, and hold exclusive global rights to therapeutics from the partnership.
Jazz secures FDA approval for Modeyso to treat rare brain tumour
Modeyso is a small molecule that acts as a protease activator and dopamine receptor inhibitor to induce apoptosis and alter mitochondrial metabolism.
SERB Pharma to acquire Y-mAbs Therapeutics for $412m
The acquisition will enhance SERB’s portfolio in rare diseases and medical emergencies, strengthening its position in the global pharmaceutical market.
SOPHiA, AstraZeneca expand AI collaboration for breast cancer
The collaboration will leverage SOPHiA’s AI Factories to generate evidence on the efficacy and real-world impact of breast cancer therapies.